RT @influenzer3: ●IL-1R阻害薬が中等~重症ARDS患者の予後を改善する可能性 →HCQ+LPV/rという抗ウイルス治療に加えて、免疫抑制剤であるIL-1R阻害薬を加える意義についての検討です。 素晴らしい成績かと。 HCQのように矛盾した結果が出てくる事も…
RT @influenzer3: ●IL-1R阻害薬が中等~重症ARDS患者の予後を改善する可能性 →HCQ+LPV/rという抗ウイルス治療に加えて、免疫抑制剤であるIL-1R阻害薬を加える意義についての検討です。 素晴らしい成績かと。 HCQのように矛盾した結果が出てくる事も…
RT @influenzer3: ●IL-1R阻害薬が中等~重症ARDS患者の予後を改善する可能性 →HCQ+LPV/rという抗ウイルス治療に加えて、免疫抑制剤であるIL-1R阻害薬を加える意義についての検討です。 素晴らしい成績かと。 HCQのように矛盾した結果が出てくる事も…
Anakinra for the WIN! “Compared with standard treatment, high-dose anakinra was associated with a higher survival rate at 21 days, with cumulative survival of 90% in the anakinra group versus 56% in the standard treatment group (p=0·009; figure 1A).” https
RT @influenzer3: ●IL-1R阻害薬が中等~重症ARDS患者の予後を改善する可能性 →HCQ+LPV/rという抗ウイルス治療に加えて、免疫抑制剤であるIL-1R阻害薬を加える意義についての検討です。 素晴らしい成績かと。 HCQのように矛盾した結果が出てくる事も…
RT @influenzer3: ●IL-1R阻害薬が中等~重症ARDS患者の予後を改善する可能性 →HCQ+LPV/rという抗ウイルス治療に加えて、免疫抑制剤であるIL-1R阻害薬を加える意義についての検討です。 素晴らしい成績かと。 HCQのように矛盾した結果が出てくる事も…
RT @ABsteward: In this small retrospective cohort study @TheLancetRheum of patients with #COVID19 and ARDS managed with non-invasive ventil…
RT @influenzer3: ●IL-1R阻害薬が中等~重症ARDS患者の予後を改善する可能性 →HCQ+LPV/rという抗ウイルス治療に加えて、免疫抑制剤であるIL-1R阻害薬を加える意義についての検討です。 素晴らしい成績かと。 HCQのように矛盾した結果が出てくる事も…
RT @influenzer3: ●IL-1R阻害薬が中等~重症ARDS患者の予後を改善する可能性 →HCQ+LPV/rという抗ウイルス治療に加えて、免疫抑制剤であるIL-1R阻害薬を加える意義についての検討です。 素晴らしい成績かと。 HCQのように矛盾した結果が出てくる事も…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @influenzer3: ●IL-1R阻害薬が中等~重症ARDS患者の予後を改善する可能性 →HCQ+LPV/rという抗ウイルス治療に加えて、免疫抑制剤であるIL-1R阻害薬を加える意義についての検討です。 素晴らしい成績かと。 HCQのように矛盾した結果が出てくる事も…
RT @giovannilandoni: We administered high doses anakinra in 29 patients with severe bilateral #COVID19 pneumonia (but not yet admitted to t…
●IL-1R阻害薬が中等~重症ARDS患者の予後を改善する可能性 →HCQ+LPV/rという抗ウイルス治療に加えて、免疫抑制剤であるIL-1R阻害薬を加える意義についての検討です。 素晴らしい成績かと。 HCQのように矛盾した結果が出てくる事もありますので、続報が待たれるところです。 https://t.co/h9R9Nm83Ze
Muy recomendable
bom, saíram os primeiros resultados da anacinra na Itália. pequeno mas promissor. https://t.co/N8D46BlWJI
We administered high doses anakinra in 29 patients with severe bilateral #COVID19 pneumonia (but not yet admitted to the ICU). The results on survival are impressive. #MicroCLOTS
RT @kazuki24_: イタリアからCOVID-19に対してのIL-1阻害薬 (anakinra)のretrospective study。 CPAPにてICU外で管理されているmoderate-to-severe ARDSかつhyperinflammationの患者に対…
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study - @TheLancetRheum #COVID19 https://t.co/RLVUIWEGDa
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
Interleukin-1 blockade with high-dose anakinra to treat #Covid_19 @SanRaffaeleMI https://t.co/2ZdXc63BIP
S'attaquer aux conséquences et pas au virus directement, ce sera certainement la solution #anakinra #Anaconda #covid19 #URCpneumoCHUdeNice
#PedsICU #COVID19 @destmauricemd @curehiv1 @OzlemEquilsMD
RT @victornizet: Inflammasome-thing to think about Retrospective cohort study of patients with COVID-19 and ARDS managed with non-invasive…
Inflammasome-thing to think about Retrospective cohort study of patients with COVID-19 and ARDS managed with non-invasive ventilation outside the ICU: high-dose anakinra (blocks IL-1R) was safe and associated with clinical improvement in 72% of patients
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @syinvesting: #COVID19 $SOBI First data from Italy of IL-1 blockade in patients with #ARDS & hyperinflammation. High-dose IV anakinra w…
@ArditiMd @yoncabulutmd @KawasakiDisease literature on anakinra in covid ards https://t.co/DIcIGLsU9r
@PMOIndia @drharshvardhan @ProfBhargava @ICMRDELHI @mybmc @TFORDCOVID19 @CSIR_IND @PremnathV6 @ICMRDELHI @rajeshtope11 🙏🙏 Appealing once again - Anakinra should be given a try for Covid19 induced #CytokineStorm @pathguy009 @ramyakannan @maryashakil ht
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
Interleukin-1 blockade with high-dose #anakinra in patients with #COVID-19, acute respiratory distress syndrome, and hyperinflammation: finally some promising results from #Milan ! #lancet #rheumatology https://t.co/PMoWZIjPR6
@Newsweek See also https://t.co/ikvhQRUZMG
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @ABsteward: In this small retrospective cohort study @TheLancetRheum of patients with #COVID19 and ARDS managed with non-invasive ventil…
RT @SRAnesthesiaICU: In this retrospective study of #COVID19 patients with ARDS managed with non-invasive ventilation outside ICU, high-dos…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
Preparar aulas sobre ensaios clínicos está fácil. Ontem, o artigo do NEJM dando feição de ensaio clínico a um estudo observacional. Hoje, esse comparando medicamentos com controles históricos. Artigos "meia boca" podem atrapalhar e causar confusão. http
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @pharmakillen: Sobi. Lancet med publikation i COVID-19 patienter som behandlats med Sobis Kineret. Ej bakom paywall. Läs för lärandet.…
RT @yachts111xenon: 組換え型インターロイキン-1受容体拮抗薬アナキンラを高用量使用した29人中21人が炎症蛋白質の低下と呼吸機能の改善が見られた. 1日目の生存率は、アナキンラ高用量群で90%、標準治療群で56%であった(p=0-009) https://…
RT @basiliu: @enriquecalvoA @txellsalles @soniaminguez_ que os parece? #anakinra a altas dosis en una fase de semicríticos comparado con tr…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @SRAnesthesiaICU: In this retrospective study of #COVID19 patients with ARDS managed with non-invasive ventilation outside ICU, high-dos…
RT @SRAnesthesiaICU: In this retrospective study of #COVID19 patients with ARDS managed with non-invasive ventilation outside ICU, high-dos…
Sobi. Lancet med publikation i COVID-19 patienter som behandlats med Sobis Kineret. Ej bakom paywall. Läs för lärandet. https://t.co/3TDnlxgnQM
RT @SRAnesthesiaICU: In this retrospective study of #COVID19 patients with ARDS managed with non-invasive ventilation outside ICU, high-dos…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @AbbateAntonio: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyper…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
Anti-IL1 in severe COVID-19 with ARDS https://t.co/3P22kkL1aM Uncontrolled trial of ant-IL1 Anakinra (ANA) Sick pts with ARDS with hyperinflammation (CRP>100mg/l) Std Rx Non invasive ventiation , HCQ , Lopinavir/ritonavir + High dose ANA iv…h
イタリアからCOVID-19に対してのIL-1阻害薬 (anakinra)のretrospective study。 CPAPにてICU外で管理されているmoderate-to-severe ARDSかつhyperinflammationの患者に対して。Day21では、生存率はhigh-dose群で90%、standard群で56% (p=0.009)と有意にhigh-dose群で高かった https://t.co/ghFN6AOD5D
RT @GiacomoMonti: Great Job from our colleagues of Immunology Dept at @SanRaffaeleMI ! Can Anakinra help in #COVID19 ? Hope to publish so…
RT @SRAnesthesiaICU: In this retrospective study of #COVID19 patients with ARDS managed with non-invasive ventilation outside ICU, high-dos…
In this retrospective study of #COVID19 patients with ARDS managed with non-invasive ventilation outside ICU, high-dose #anakinra quenched hyper-inflammation, improved respiration, and reduced death and need for ICU admission. https://t.co/suIhHuHYny #FOA
RT @CyrilPedia: 'In this retrospective cohort study of patients with COVID-19 and ARDS managed with non-invasive ventilation outside of the…
RT @AbbateAntonio: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyper…
RT @ABsteward: In this small retrospective cohort study @TheLancetRheum of patients with #COVID19 and ARDS managed with non-invasive ventil…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @GilbertDeray: Un antagoniste de IL1 qui semble efficace dans les formes graves de Covid19. Une étude encourageante mais qui demande con…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
'In this retrospective cohort study of patients with COVID-19 and ARDS managed with non-invasive ventilation outside of the ICU, treatment with high-dose anakinra was safe and associated with clinical improvement in 72% of patients.' https://t.co/uVZCPphR
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @philipcrobinson: Retrospective ICU cohort study from Italy of anakinra (anti-IL-1) in COVID-19. Survival 90% versus 56% from @TheLancet…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @philipcrobinson: Retrospective ICU cohort study from Italy of anakinra (anti-IL-1) in COVID-19. Survival 90% versus 56% from @TheLancet…
Retrospective ICU cohort study from Italy of anakinra (anti-IL-1) in COVID-19. Survival 90% versus 56% from @TheLancetRheum Need more data though https://t.co/OS3YSYMfTM
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
Nu tycker jag ju inte att Cantargia skall hoppa på Covid-19 tåget men användningsområdena för blockering av IL-1 som Cantargias antikroppar blockerar verkar ju vara betydligt fler än Cancer och Autoimmuna sjukdomar! https://t.co/eOLI5pYxYj
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @Noboru_Hagino: 本当にサイトカインストームなんだったら、抑えるサイトカインはinnate immunity寄りが良いのではないかということで、IL-1RAであるAnakinraのCOVID-19に対する報告。 Kaplan-Meier見ると良さげな雰囲気…
Great Job from our colleagues of Immunology Dept at @SanRaffaeleMI ! Can Anakinra help in #COVID19 ? Hope to publish soon results from ICU-patients ! @SRAnesthesiaICU https://t.co/rCaDhG4LuM https://t.co/wLwy2ekHqn
RT @EricBillyFR: Étude rétrospective avec un anti-IL1R. Comme toujours les auteurs concluent qu’il faut in étude RCT pour confirmer les eff…
👨🏻⚕️👨🏻⚕️👨🏻⚕️
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
Étude rétrospective avec un anti-IL1R. Comme toujours les auteurs concluent qu’il faut in étude RCT pour confirmer les effets bénéfiques.
RT @drjohnmorley: Makes sense when given when patients severely ill not too early
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study https://t.co/qpabyEopRi
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
@enriquecalvoA @txellsalles @soniaminguez_ que os parece? #anakinra a altas dosis en una fase de semicríticos comparado con tratamiento convencional. No sé cuál será la opinión de compañeros que han utilizado más #Tocilizumab 🤔 @IvanCastellvi @cesardiaztor
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @Noboru_Hagino: 本当にサイトカインストームなんだったら、抑えるサイトカインはinnate immunity寄りが良いのではないかということで、IL-1RAであるAnakinraのCOVID-19に対する報告。 Kaplan-Meier見ると良さげな雰囲気…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
⤵️ anti-IL1 dans #COVID19 un nouvel ingrédient pour le cocktail 🍹 !? Bientôt plus assez de place dans le shaker ...
Un antagoniste de IL1 qui semble efficace dans les formes graves de Covid19. Une étude encourageante mais qui demande confirmation dans un essai avec un groupe contrôle. https://t.co/swnscSZaQa
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…